COVID-19 is the current sickle cell vaccine name. What does it mean, and should you get it? Dr. Wally R. Smith, Florence Neal Cooper Smith Professor of Sickle Cell Disease and Medical Director of the adult sickle cell program at VCU Health, answers the questions about COVID-19 and why it might be harmful for people with sickle cell disease. Then, he offers a list of other vaccine names to consider.
PPSV23 vaccine
The PPSV23 vaccine for sickle cell disease is a pneumococcal polysaccharide vaccine. This vaccine is used to prevent and treat sickle cell disease. It is administered to patients aged 6 years and older. For children with an increased risk for sickle cell disease, two doses of the PPSV23 vaccine should be given. Children should receive the second dose of the vaccine at least five years after the first.
The risk of serious adverse reactions is higher in patients with SCD and HIV, and in children and adolescent patients. The health care provider should closely monitor patients for any adverse reactions after receiving PPSV23 vaccination. It is recommended that a period of at least four weeks is allowed between PCV13 and PPSV23 vaccination. In addition, PPSV23 should not be administered at the same time as PCV13.
In children aged two through eight years and adults with immune-compromising conditions, the PPSV23 vaccine should be administered as soon as possible. The vaccine should be administered at least five years after the last dose of PCV13. Moreover, the PPSV23 vaccine should not be administered intradermally because it may cause local reactions. Therefore, it should be administered intramuscularly. In children and adults with sickle cell disease, it is recommended to receive two doses of PPSV23 vaccine.
The PPSV23 vaccine for sickle cell disease is not recommended for children under two years of age. The vaccine is indicated for children with an immunodeficiency of selective IgA. Children younger than two years of age should receive PCV13 first, and then PPSV23 eight weeks later. PCV15 and PCV20 should not be given to children. A child should also receive the PCV13 vaccine for sickle cell disease.
PNEUMOVAX 23 is a clear, colorless solution of 25 micrograms of polysaccharide type. Moreover, it contains 0.25% phenol. It should be administered directly, without dilution. Moreover, it does not contain natural rubber latex. It is manufactured using synthetic latex. However, children should not receive the vaccine if it contains particulate matter.
PPSV22 vaccine
Although PPSV23 vaccination is generally recommended for immune-competent individuals, there is some controversy about its use in children. While a PPSV22 vaccine is safe, some experts are unsure of its effectiveness. In addition, children who have been exposed to pneumococcal disease are particularly vulnerable. Pneumococcal disease can be fatal and can develop in a child as early as 23 months old. The new conjugate pneumococcal vaccines may reduce the incidence of infection in children with sickle cell disease. These vaccines should be administered intramuscularly, but should not be given intradermally.
Children aged two years and older should receive a single dose of PPSV23. Depending on the condition of the child, they may require one or two doses of PPSV23. The first dose of PPSV23 should be given eight weeks after the first dose of PCV13. Other vaccinations for children are recommended by the ACIP. The ACIP recommends PPSV23 and PCV13 for children and adults.
Podobne tematy